Virtual Engineering Days

ARBURG to present on medical applications

02.06.2021
ARBURG, partnered with Evonik and the University of East Anglia, will highlighting unique medical applications enabled by APF (ARBURG Plastic Freeforming) technology. The secession cover several medical applications with a focus on Implantable Materials and Pharmaceuticals (Printed Medication). 

Cross heading: Unique Medical Applications with APF
Pellet based 3D printing allows users to print real materials, opening up a variety of unique medical applications. Join ARBURG's Gerry Berberian, as he highlights unique applications enabled by the APF technology. This session will cover several medical applications but focuses on two main areas: Implantable Materials; and Pharmaceuticals (Printed Medication). Hear Balaji Prabhu of Evonik and Dr. Sheng Qi of the University of East Anglia’s School of Pharmacy share their experiences and results achieved when printing with their own materials.

Event Details
Date: June 16, 2021
Time: 11:45 am Eastern Standard Time
Register free: https://www.engineeringwk.com/en/home.html

Balaji Prabhu is the Director of Strategic Marketing, Medical Device Solutions at Evonik. He is responsible for managing strategic growth of the Medical Device Biomaterials portfolio. Formerly as Director of Innovation for Evonik Health Care, Balaji was one of the first members instrumental in setting up of this Medical Device Competence Center (MDCC) in Birmingham, Alabama which was an internal startup funded by Evonik Corporate & Business Lines. This center is also the 3D printing Center of Excellence for bioresorbable polymers developing cutting edge biomaterial solutions for medical device applications.

Dr Qi's research addresses innovation in pharmaceutical materials and manufacturing resulting in over 70 peer-reviewed publications, 2 patent fillings, 6 book chapters (2 in pharmaceutical additive manufacturing) and one co-edited book on pharmaceutical 3Dprinting. Her research has attracted more than £2.5 M funding from the UK government, EU and industry. For material extrusion-additive manufacturing (ME-AM) of pharmaceutical solid dosage forms, her lab focuses on the development of fit-for-purpose pharmaceutical 3D printing process and the use of microstructure to control drug release performance of 3D printed solid dosage forms. She has a strong cross-disciplinary network of collaborations with other academic institutions, AM instrument manufacturers, pharma and excipient companies as well as UK NHS hospitals, patients, pharmacists, and clinicians.

Read ARBURG’s case study featuring Dr Qi’s work here.